Zentalis Pharmaceuticals Stock Forecast
NASDAQ: ZNTLHealth CareBiotechnology: Pharmaceutical PreparationsUSD
At close: Oct 9, 4:00 PM ET · Delayed 15 min
ZNTL analyst consensus
Consensus (11 analysts)
buy
Avg. price target
$7.33+177.65%
- Strong buy 0
- Buy 7
- Hold 4
- Sell 0
- Strong sell 0
Target range
Ratings and targets reflect third-party analyst opinions, not MetaCap recommendations.
What analysts say
According to 11 Wall Street analysts covering Zentalis Pharmaceuticals (2026-10-09), 7 rate the stock a buy or strong buy, 4 rate it a hold and 0 rate it a sell or strong sell, for a consensus rating of "buy". The average 12-month price target is $7.33, with a high estimate of $10.00 and a low estimate of $5.00. The average target implies upside of 177.7% from the current price of $2.64.
The spread between the highest and lowest targets is 100.0%, a wide range that reflects significant disagreement among analysts. Price targets and ratings are the opinions of third-party analysts, not MetaCap. They are frequently revised and have a mixed track record, so treat them as one input among many for ZNTL.
Summary generated from market data by MetaCap's automated system. Methodology
Rating distribution
| Rating | Analysts | Share |
|---|---|---|
| Strong buy | 0 | 0% |
| Buy | 7 | 64% |
| Hold | 4 | 36% |
| Sell | 0 | 0% |
| Strong sell | 0 | 0% |
Ratings as of 2026-10-09.
Price target scenarios
| Target | Price | vs. current |
|---|---|---|
| Low target | $5.00 | +89.39% |
| Average target | $7.33 | +177.65% |
| High target | $10.00 | +278.79% |